Overexpression of mutant ataxin-3 in mouse cerebellum induces ataxia and cerebellar neuropathology

Cerebellum

Volumn 12, Issue 4, 2013, Pages 441-455

  Nóbrega, Clévio ^a   Nascimento Ferreira, Isabel ^a,b,d   Onofre, Isabel ^a,b   Albuquerque, David ^a,c   Conceição, Mariana ^a,b   Déglon, Nicole ^e   De Almeida, Luís Pereira ^a,b  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b UNIVERSITY OF COIMBRA   (Portugal)

^c UNIVERSITY OF COIMBRA   (Portugal)

^d Molecular Imaging Research Center   (France)

^e LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Ataxin 3 .Cerebellum .Machado Josephdisease; In vivo; Lentiviral vectors; Mousemodel of disease

Indexed keywords

ATAXIN 3; LENTIVIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR DISORDER; BRAIN REGION; CEREBELLUM CORTEX; CONTROLLED STUDY; GAIT DISORDER; HYPERACTIVITY; IMMUNOREACTIVITY; MACHADO JOSEPH DISEASE; MOTOR COORDINATION; MOTOR DYSFUNCTION; MOUSE; NERVE CELL DEGENERATION; NEUROPATHOLOGY; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION;

EID: 84892368975     PISSN: 14734222     EISSN: 14734230     Source Type: Journal    
DOI: 10.1007/s12311-012-0432-0     Document Type: Article

References (58)

1. Orr HT, Zoghbi HY. Trinucleotide repeat disorders. Annu Rev Neurosci. 2007;30:575-621.
2. Katsuno M, Banno H, Suzuki K, Takeuchi Y, Kawashima M, Tanaka F, et al. Molecular genetics and biomarkers of polyglutamine diseases. Curr Mol Med. 2008;8(3):221-34.
3. Schmidt T, Landwehrmeyer GB, Schmitt I, Trottier Y, Auburger G, Laccone F, et al. An isoform of ataxin-3 accumulates in the nucleus of neuronal cells in affected brain regions of SCA3 patients. Brain Pathol. 1998;8(4):669-79.
4. Kawaguchi Y, Okamoto T, Taniwaki M, Aizawa M, Inoue M, Katayama S, et al. CAG expansions in a novel gene for Machado-Joseph disease at chromosome 14q32.1. Nat Genet. 1994;8(3):221-8.
5. Takiyama Y, Sakoe K, Nakano I, Nishizawa M. Machado-Joseph disease: cerebellar ataxia and autonomic dysfunction in a patient with the shortest known expanded allele (56 CAG repeat units) of the MJD1 gene. Neurology. 1997;49(2):604-6.
6. Maciel P, Costa MC, Ferro A, Rousseau M, Santos CS, Gaspar C, et al. Improvement in the molecular diagnosis of Machado-Joseph disease. Arch Neurol. 2001;58(11):1821-7.
7. Sudarsky L, Coutinho P. Machado-Joseph disease. Clin Neurosci. 1995;3(1):17-22.
8. Gwinn-Hardy K, Singleton A, O'Suilleabhain P, Boss M, Nicholl D, Adam A, et al. Spinocerebellar ataxia type 3 phenotypically resembling parkinson disease in a black family. Arch Neurol. 2001;58(2):296-9.
9. Nishiyama K, Murayama S, Goto J, Watanabe M, Hashida H, Katayama S, et al. Regional and cellular expression of the Machado-Joseph disease gene in brains of normal and affected individuals. Ann Neurol. 1996;40(5):776-81.
10. Paulson HL, Das SS, Crino PB, PerezMK, Patel SC, Gotsdiner D, et al. Machado-Joseph disease gene product is a cytoplasmic protein widely expressed in brain. Ann Neurol. 1997;41(4):453-62.
11. Wullner U, Reimold M, Abele M, Burk K, Minnerop M, Dohmen BM, et al. Dopamine transporter positron emission tomography in spinocerebellar ataxias type 1, 2, 3, and 6. Arch Neurol. 2005;62 (8):1280-5.
12. Alves S, Regulier E, Nascimento-Ferreira I, Hassig R, Dufour N, Koeppen A, et al. Striatal and nigral pathology in a lentiviral rat model of Machado-Joseph disease. Hum Mol Genet. 2008;17 (14):2071-83.
13. Scherzed W, Brunt ER, Heinsen H, de Vos RA, Seidel K, Burk K, Schols L, Auburger G, Del Turco D, Deller T, Korf HW, den Dunnen WF, Rub U. Pathoanatomy of cerebellar degeneration in spinocerebellar ataxia type 2 (SCA2) and type 3 (SCA3). Cerebellum. 2012;11:749-60.
14. Ikeda H, Yamaguchi M, Sugai S, Aze Y, Narumiya S, Kakizuka A. Expanded polyglutamine in the Machado-Joseph disease protein induces cell death in vitro and in vivo. Nat Genet. 1996;13(2):196-202.
15. Cemal CK, Carroll CJ, Lawrence L, Lowrie MB, Ruddle P, Al-Mahdawi S, et al. YAC transgenic mice carrying pathological alleles of the MJD1 locus exhibit a mild and slowly progressive cerebellar deficit. Hum Mol Genet. 2002;11(9):1075-94.
16. Goti D, Katzen SM, Mez J, Kurtis N, Kiluk J, Ben-Haiem L, et al. A mutant ataxin-3 putative-cleavage fragment in brains of Machado-Joseph disease patients and transgenic mice is cytotoxic above a critical concentration. J Neurosci. 2004;24(45):10266-79.
17. Bichelmeier U, Schmidt T, Hubener J, Boy J, Ruttiger L, Habig K, et al. Nuclear localization of ataxin-3 is required for the manifestation of symptoms in SCA3: in vivo evidence. J Neurosci. 2007;27(28):7418-28.
18. Torashima T, Koyama C, Iizuka A, Mitsumura K, Takayama K, Yanagi S, et al. Lentivector-mediated rescue from cerebellar ataxia in a mouse model of spinocerebellar ataxia. EMBO Rep. 2008;9 (4):393-9.
19. Boy J, Schmidt T, Schumann U, Grasshoff U, Unser S, Holzmann C, et al. A transgenic mouse model of spinocerebellar ataxia type 3 resembling late disease onset and gender-specific instability of CAG repeats. Neurobiol Dis. 2010;37(2):284-93.
20. Silva-Fernandes A, Costa Mdo C, Duarte-Silva S, Oliveira P, Botelho CM, Martins L, et al. Motor uncoordination and neuropathology in a transgenic mouse model of Machado-Joseph disease lacking intranuclear inclusions and ataxin-3 cleavage products. Neurobiol Dis. 2010;40(1):163-76.
21. Mangiarini L, Sathasivam K, Seller M, Cozens B, Harper A, Hetherington C, Lawton M, Trottier Y, Lehrach H, Davies SW, Bates GP. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell. 1996;87:493-506.
22. Hodgson JG, Agopyan N, Gutekunst CA, Leavitt BR, LePiane F, Singaraja R, Smith DJ, Bissada N, McCutcheon K, Nasir J, Jamot L, Li XJ, Stevens ME, Rosemond E, Roder JC, Phillips AG, Rubin EM, Hersch SM, Hayden MR. A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration. Neuron. 1999;23:181-92.
23. de Almeida LP, Ross CA, Zala D, Aebischer P, Deglon N. Lentiviral-mediated delivery of mutant huntingtin in the striatum of rats induces a selective neuropathology modulated by polyglutamine repeat size, huntingtin expression levels, and protein length. J Neurosci. 2002;22(9):3473-83.
24. Lo Bianco C, Ridet JL, Schneider BL, Deglon N, Aebischer P. alpha-Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease. Proc Natl Acad Sci U S A. 2002;99(16):10813-8.
25. Kirik D, Annett LE, Burger C, Muzyczka N, Mandel RJ, Bjorklund A. Nigrostriatal alpha-synucleinopathy induced by viral vector-mediated overexpression of human alpha-synuclein: a new primate model of Parkinson's disease. Proc Natl Acad Sci U S A. 2003;100(5):2884-9.
26. Lauwers E, Debyser Z, Van Dorpe J, De Strooper B, Nuttin B, Baekelandt V. Neuropathology and neurodegeneration in rodent brain induced by lentiviral vector-mediated overexpression of alpha-synuclein. Brain Pathol. 2003;13(3):364-72.
27. de Almeida LP, Zala D, Aebischer P, Deglon N. Neuroprotective effect of a CNTF-expressing lentiviral vector in the quinolinic acid rat model of Huntington's disease. Neurobiol Dis. 2001;8(3):433-46.
28. Torashima T, Okoyama S, Nishizaki T, Hirai H. In vivo transduction of murine cerebellar Purkinje cells by HIV-derived lentiviral vectors. Brain Res. 2006;1082(1):11-22.
29. Torashima T, Yamada N, Itoh M, Yamamoto A, Hirai H. Exposure of lentiviral vectors to subneutral pH shifts the tropism from Purkinje cell to Bergmann glia. Eur J Neurosci. 2006;24(2):371-80.
30. Takayama K, Torashima T, Horiuchi H, Hirai H. Purkinje-cellpreferential transduction by lentiviral vectors with the murine stem cell virus promoter. Neurosci Lett. 2008;443(1):7-11.
31. Lange W. Cell number and cell density in the cerebellar cortex of man and some other mammals. Cell Tissue Res. 1975;157:115-24.
32. Everett CM, Wood NW. Trinucleotide repeats and neurodegenerative disease. Brain. 2004;127(Pt 11):2385-405.
33. Zoghbi HY, Orr HT. Glutamine repeats and neurodegeneration. Annu Rev Neurosci. 2000;23:217-47.
34. Ito M. Historical review of the significance of the cerebellum and the role of Purkinje cells in motor learning. Ann N Y Acad Sci. 2002;978:273-88.
35. Durr A, Stevanin G, Cancel G, Duyckaerts C, Abbas N, Didierjean O, et al. Spinocerebellar ataxia 3 and Machado-Joseph disease: clinical, molecular, and neuropathological features. Ann Neurol. 1996;39(4):490-9.
36. Xia X, Zhou H, Huang Y, Xu Z. Allele-specific RNAi selectively silences mutant SOD1 and achieves significant therapeutic benefit in vivo. Neurobiol Dis. 2006;23(3):578-86.
37. Sawada Y, Kajiwara G, Iizuka A, Takayama K, Shuvaev AN, Koyama C, et al. High transgene expression by lentiviral vectors causes maldevelopment of Purkinje cells in vivo. Cerebellum. 2010;9(3):291-302.
38. Hirai H. Progress in transduction of cerebellar Purkinje cells in vivo using viral vectors. Cerebellum. 2008;7(3):273-8.
39. Oue M, Mitsumura K, Torashima T, Koyama C, Yamaguchi H, Furuya N, et al. Characterization of mutant mice that express polyglutamine in cerebellar Purkinje cells. Brain Res. 2009;1255:9-17.
40. Koeppen AH. The pathogenesis of spinocerebellar ataxia. Cerebellum. 2005;4(1):62-73.
41. Munoz E, Rey MJ, Mila M, Cardozo A, Ribalta T, Tolosa E, et al. Intranuclear inclusions, neuronal loss and CAG mosaicism in two patients with Machado-Joseph disease. J Neurol Sci. 2002;200(1-2):19-25.
42. Rub U, de Vos RA, Brunt ER, Schultz C, Paulson H, Del Tredici K, et al. Degeneration of the external cuneate nucleus in spinocerebellar ataxia type 3 (Machado-Joseph disease). Brain Res. 2002;953(1-2):126-34.
43. Rub U, de Vos RA, Schultz C, Brunt ER, Paulson H, Braak H. Spinocerebellar ataxia type 3 (Machado-Joseph disease): severe destruction of the lateral reticular nucleus. Brain. 2002;125(Pt 9):2115-24.
44. Chou AH, Yeh TH, Ouyang P, Chen YL, Chen SY, Wang HL. Polyglutamine-expanded ataxin-3 causes cerebellar dysfunction of SCA3 transgenic mice by inducing transcriptional dysregulation. Neurobiol Dis. 2008;31(1):89-101.
45. Sarna JR, Hawkes R. Patterned Purkinje cell death in the cerebellum. Prog Neurobiol. 2003;70(6):473-507.
46. Schilling G, Jinnah HA, Gonzales V, Coonfield ML, Kim Y, Wood JD, et al. Distinct behavioral and neuropathological abnormalities in transgenic mouse models of HD and DRPLA. Neurobiol Dis. 2001;8(3):405-18.
47. Luesse HG, Schiefer J, Spruenken A, Puls C, Block F, Kosinski CM. Evaluation of R6/2 HD transgenic mice for therapeutic studies in Huntington's disease: behavioral testing and impact of diabetes mellitus. Behav Brain Res. 2001;126(1-2):185-95.
48. Menalled LB, Sison JD, Dragatsis I, Zeitlin S, Chesselet MF. Time course of early motor and neuropathological anomalies in a knockin mouse model of Huntington's disease with 140 CAG repeats. J Comp Neurol. 2003;465(1):11-26.
49. Nguyen HP, Kobbe P, Rahne H, Worpel T, Jager B, Stephan M, et al. Behavioral abnormalities precede neuropathological markers in rats transgenic for Huntington's disease. Hum Mol Genet. 2006;15 (21):3177-94.
50. Reddy PH, Charles V, Williams M, Miller G, Whetsell Jr WO, Tagle DA. Transgenic mice expressing mutated full-length HD cDNA: a paradigm for locomotor changes and selective neuronal loss in Huntington's disease. Philos Trans R Soc Lond B Biol Sci. 1999;354(1386):1035-45.
51. Slow EJ, van Raamsdonk J, Rogers D, Coleman SH, Graham RK, Deng Y, et al. Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease. HumMol Genet. 2003;12(13):1555-67.
52. van der Staay FJ, Kerbusch S, RaaijmakersW. Genetic correlations in validating emotionality. Behav Genet. 1990;20(1):51-62.
53. Zawacki TM, Grace J, Paul R, Moser DJ, Ott BR, Gordon N, et al. Behavioral problems as predictors of functional abilities of vascular dementia patients. J Neuropsychiatry Clin Neurosci. 2002;14 (3):296-302.
54. Boy J, Schmidt T, Wolburg H, Mack A, Nuber S, Bottcher M, Schmitt I, Holzmann C, Zimmermann F, Servadio A and Riess O. Reversibility of symptoms in a conditional mouse model of spinocerebellar ataxia type 3. Hum Mol Genet. 2009;18(22):4282-95.
55. Picciotto MR,Wickman K. Using knockout and transgenic mice to study neurophysiology and behavior. Physiol Rev. 1998;78 (4):1131-63.
56. Alves S, Nascimento-Ferreira I, Auregan G, Hassig R, Dufour N, Brouillet E, Pedroso de Lima MC, Hantraye P, Pereira de Almeida L, Deglon N. Allele-specific RNA silencing of mutant ataxin-3 mediates neuroprotection in a rat model of Machado-Joseph disease. PLoS One. 2008;3:e3341.
57. Brown SD, Chambon P, de Angelis MH. EMPReSS: standardized phenotype screens for functional annotation of the mouse genome. Nat Genet. 2005;37(11):1155.
58. Green EC, Gkoutos GV, Lad HV, Blake A,Weekes J, Hancock JM. EMPReSS: European mouse phenotyping resource for standardized screens. Bioinformatics. 2005;21(12):2930-1.